Key facts
| Price (PPV) | 83,578 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | risdiplam |
| Class | Other drugs for musculo-skeletal disorders |
| ATC code | M09AX10 |
| Manufacturer | ROCHE S.A |
| Presentation | 1 flacon de 2g de poudre pour solution buvable, avec 1 adaptateur pour flacon, deux seringues orales ambrées graduées réutilisables de 6 ml, et deux seringues orales ambrées graduées réutilisables de 12 ml |
| Hospital price | 81,948 MAD |
| Data collected on | 9/8/2026 |
Indications
Evrysdi est indiqué dans le traitement de l'amyotrophie spinale (SMA) 5q chez les patients pédiatriques et adultes. Source : Compendium.ch - Date : 20 octobre 2025
Find an open pharmacy
On-call pharmacies near you
About Evrysdi 0.75 mg / ml
Evrysdi 0.75 mg / ml belongs to the other drugs for musculo-skeletal disorders therapeutic class. In Morocco, this drug is marketed by ROCHE S.A and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Evrysdi 0.75 mg / ml, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Evrysdi 0.75 mg / ml
Answers to common questions from Moroccan patients about this drug.